These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
84. Acute and subchronic effects of low-dose bromocriptine in haloperidol-treated schizophrenics. Gattaz WF; Rost W; Hübner CK; Bauer K Biol Psychiatry; 1989 Feb; 25(3):247-55. PubMed ID: 2643996 [TBL] [Abstract][Full Text] [Related]
85. Melperone in the treatment of schizophrenia. Bjerkenstedt L Acta Psychiatr Scand Suppl; 1989; 352():35-9. PubMed ID: 2479227 [TBL] [Abstract][Full Text] [Related]
86. Plasma levels of phenylacetic acid, m- and p-hydroxyphenylacetic acid, and platelet monoamine oxidase activity in schizophrenic and other patients. Davis BA; Yu PH; Carlson K; O'Sullivan K; Boulton AA Psychiatry Res; 1982 Feb; 6(1):97-105. PubMed ID: 6120530 [TBL] [Abstract][Full Text] [Related]
87. Electroencephalography in schizophrenic patients: comparison between neuroleptic-naive state and after treatment. Nagase Y; Okubo Y; Toru M Biol Psychiatry; 1996 Sep; 40(6):452-6. PubMed ID: 8879464 [TBL] [Abstract][Full Text] [Related]
88. Involuntary disorders of movement in chronic schizophrenia--the role of the illness and its treatment. Owens DG Psychopharmacology Suppl; 1985; 2():79-87. PubMed ID: 2860663 [TBL] [Abstract][Full Text] [Related]
90. Plasma and cerebrospinal fluid interleukin-1 beta and interleukin-6 in hospitalized schizophrenic patients. Katila H; Hurme M; Wahlbeck K; Appelberg B; Rimón R Neuropsychobiology; 1994; 30(1):20-3. PubMed ID: 7969854 [TBL] [Abstract][Full Text] [Related]
91. ERPs in schizophrenia: effects of antipsychotic medication. Ford JM; White PM; Csernansky JG; Faustman WO; Roth WT; Pfefferbaum A Biol Psychiatry; 1994 Aug; 36(3):153-70. PubMed ID: 7948453 [TBL] [Abstract][Full Text] [Related]
92. [14C]-beta-phenethylamine, its distribution after administration by various routes to cats, and the effects of monoamine oxidase inhibitors. Garcha G; Imrie PR; Marley E; Thomas DV Br J Pharmacol; 1985 Dec; 86(4):877-88. PubMed ID: 4075021 [TBL] [Abstract][Full Text] [Related]
93. Gender differences in neuroleptic nonresponsive clozapine-treated schizophrenics. Szymanski S; Lieberman J; Pollack S; Kane JM; Safferman A; Munne R; Umbricht D; Woerner M; Masiar S; Kronig M Biol Psychiatry; 1996 Feb; 39(4):249-54. PubMed ID: 8645771 [TBL] [Abstract][Full Text] [Related]
94. Neuroleptic effects on serine and glycine metabolism. Baruah S; Waziri R; Sherman A Biol Psychiatry; 1993 Oct; 34(8):544-50. PubMed ID: 7903868 [TBL] [Abstract][Full Text] [Related]
95. Altered phospholipid metabolism in schizophrenia: a phosphorus 31 nuclear magnetic resonance spectroscopy study. Weber-Fahr W; Englisch S; Esser A; Tunc-Skarka N; Meyer-Lindenberg A; Ende G; Zink M Psychiatry Res; 2013 Dec; 214(3):365-73. PubMed ID: 24045051 [TBL] [Abstract][Full Text] [Related]
96. Discrimination between and among schizophrenics and other pathologies using a Spanish version of the Whitaker Index of Schizophrenic Thinking. Godoy JF; Fernandez M; Muela JA; Roldan G; Catena A; Puente AE J Clin Psychol; 1994 Mar; 50(2):158-61. PubMed ID: 8014238 [TBL] [Abstract][Full Text] [Related]